Medirazin

Alfacalcidol, the active ingredient in Medirazin, is a vitamin D analog presented as an oral dosage form for oral use. It is used to manage calcium metabolism disorders such as renal osteodystrophy, hypocalcemia due to hypoparathyroidism, and osteoporosis.

GNH USA supplies Medirazin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Alfacalcidol is a vitamin D analog that influences calcium and phosphate metabolism in bone and mineral disorders. - Renal osteodystrophy: helps normalize calcium and phosphate levels and improves bone mineralisation. - Hypocalcemia due to hypoparathyroidism: increases intestinal calcium absorption to raise serum calcium. - Osteoporosis: supports bone remodelling and may reduce fracture risk when used as part of therapy.

Alfacalcidol may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypercalcemia: elevated blood calcium causing nausea, fatigue or polyuria. - Hyperphosphatemia: increased serum phosphate levels. - Gastrointestinal discomfort: nausea, vomiting or abdominal pain. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Nephrolithiasis: kidney stone formation due to calcium excess. - Hypercalcemic crisis: severe hypercalcemia with cardiac arrhythmias. - Allergic reactions: rash, pruritus or anaphylaxis.

When prescribing Alfacalcidol, clinicians should consider several safety measures. - Monitor serum calcium: regular testing to avoid hypercalcemia. - Assess renal function: adjust use in patients with impaired kidney function. - Evaluate vitamin D status: avoid concurrent high‑dose vitamin D supplements. - Use cautiously in elderly: increased risk of hypercalcemia. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Alfacalcidol can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Thiazide diuretics: may increase risk of hypercalcemia. - Calcium supplements: additive effect on calcium levels. - Vitamin D analogues (e.g., calcitriol): can cause excessive calcium.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - Corticosteroids: may counteract vitamin D effects on bone. - Loop diuretics: may affect calcium excretion.